How many drugs treat General anesthesia?

Drug Landscape tracks 10 marketed treatments for General anesthesia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/general-anesthesia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

General anesthesia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

General anesthesia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating General anesthesia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nimbex	CISATRACURIUM	AbbVie	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1995-01-01
Nimbex	Cisatracurium Besylate	AbbVie	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1995-01-01
Rocuronium	Rocuronium Bromide	Merck & Co.	Nondepolarizing neuromuscular blocking agent	Cholinergic receptors at the motor end-plate	1994-01-01
Zemuron	ROCURONIUM	Fresenius Kabi	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1994-01-01
Suprane	DESFLURANE	Baxter	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01
Mivacron	MIVACURIUM	AbbVie	Nondepolarizing Neuromuscular Blocker	Acetylcholine receptor	1992-01-01
Diprivan	Propofol	Fresenius Kabi	General anesthetic	GABA A receptors	1989-01-01
Cysteine Hydrochloride	CYSTEINE	Exela Pharma	Vitamin C [EPC]	Cystine/glutamate transporter	1986-01-01
Alfenta	ALFENTANIL	Rising	Opioid Agonist	Mu-type opioid receptor	1986-01-01
Versed	midazolam	Generic (originally Roche)	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in General anesthesia
Pfizer · 4 drugs in General anesthesia
Baxter · 3 drugs in General anesthesia
AbbVie · 3 drugs in General anesthesia
Fresenius Kabi · 2 drugs in General anesthesia
Bausch Health · 2 drugs in General anesthesia
Ph Health · 2 drugs in General anesthesia
Rising · 2 drugs in General anesthesia
Baxter Hlthcare · 1 drug in General anesthesia
Exela Pharma · 1 drug in General anesthesia
Endo · 1 drug in General anesthesia
Charles University, Czech Republic · 1 drug in General anesthesia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in General anesthesia:

Cite this brief

Drug Landscape (2026). General anesthesia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/general-anesthesia. Accessed 2026-06-10.

General anesthesia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing